ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
MONTROUGE, France, Feb. 8, 2016 -- DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced that Charles Ruban, Chief Commercial Officer, and Susanna Mesa, Vice President of Finance, Investor Relations & Strategy, will present at LEERINK Partners 5th Annual Global Healthcare Conference on Wednesday, February 10th, 2016 at
3:55 pm ET at the Waldorf Astoria Hotel in New York, NY.
A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website, http://www.dbv-technologies.com/en/investor-relations. A replay will also be available 48 hours after the event.
DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies - a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation and Breakthrough Therapy designation from the U.S. Food and Drug Administration.
About DBV Technologies
DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com
| DBV Technologies Contacts | |
|
Nathalie Donne Director, Corporate Communication & Business Development Tel. : +33 (0)1 55 42 78 72 [email protected] |
Susanna Mesa VP of Finance, Investor Relations & Strategy Tel. : +1 212-271-0861 [email protected] |
|
DBV Technologies Media Contacts US & Europe |
|
|
Marion Janic Rooney & Associates Tel. : +1 212-223-4017 [email protected] |
Caroline Carmagnol Alize RP - Relation Presse Tel. : +33 (0)6 64 18 99 59 [email protected] |
PDF Version http://hugin.info/156437/R/1984165/727364.pdf
HUG#1984165
